SRF174

SRF174 is an investigational immuno-oncology agent developed by Surface Oncology, a clinical-stage biotechnology company focused on therapies targeting the tumor microenvironment. Limited public information is available on its specific mechanism of action, target, or clinical status, as it does not appear in major clinical trial registries, FDA documents, or recent oncology development pipelines based on available data. It may represent an early-stage or discontinued program from Surface Oncology's portfolio, which has included other SRF-series candidates like SRF617 (anti-CD39 antibody) and SRF388 (anti-IL-27 antibody) in Phase 1/2 trials for solid tumors. No details on indications, preclinical data, or partnerships have been disclosed publicly.